Compare Incyte Corporation (INCY) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs RLX Technology Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: Incyte Corporation is far larger — about 10.1× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RLX | |
|---|---|---|
Market Cap | $24.54B | $2.42B |
Sector | Health | Technology |
52-Week High | $129.93 | $2.73 |
52-Week Low | $81.61 | $1.79 |
Enterprise Value | $20.04B | $1.04B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
RLX Technology trades at $2.02, up 1.0% with bearish technical signals despite recent earnings misses. The company maintains strong profitability with 22.47% net margins and international expansion driving revenue growth from $3.62B to $4.4B. Cash flow trends show operational strength but negative net cash flow. Analyst coverage remains limited with a single hold rating.
RLX faces execution risks from international integration while trading at reasonable valuations (P/E 17.96). The upcoming Q2 2026 earnings on August 14 will be crucial for validating growth trajectory amid competitive and regulatory pressures in the global e-vapor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
